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S U M M A R Y
Introduction: Brucellosis is the most prevalent bacterial zoonosis worldwide. In this study, we aimed to
compare our 1028 brucellosis cases with other big series in the literature in view of epidemiological,
clinical, and laboratory ﬁndings and therapeutic features.
Methods: A total of 1028 brucellosis cases admitted to the Department of Infectious Diseases and Clinical
Microbiology over a 10-year period were included in the study. A retrospective analysis was undertaken
and patient ﬁles were reviewed for history, clinical and laboratory ﬁndings, and therapeutic features, as
well as complications.
Results: Of the 1028 patients, 539 (52.4%) were female and 489 (47.6%) were male. The mean age of
patients was 33.7  16.34 years and 69.6% of cases were aged 13–44 years. Four hundred and thirty-ﬁve
cases (42.3%) had a history of raising livestock and 55.2% of the cases were found to have no occupational risk
for brucellosis. Six hundred and ﬁfty-four of the cases (63.6%) had a history of raw milk and dairy products
consumption. The most frequently seen symptoms were arthralgia (73.7%) and fever (72.2%), while the most
common clinical ﬁndingswere fever (28.8%) and hepatomegaly (20.6%). Themost frequent laboratory ﬁnding
was a high C-reactive protein level (58.4%). The standard tube agglutination (STA) test + Coombs STA test was
positive in 1016 cases (98.8%). Focal involvement was present in 371 (36.1%) cases. The most frequent
involvement was osteoarticular involvement with 260 cases (25.3%). The overall relapse rate for patients
with brucellosis was 4.7%. The highest relapse rate, 8.5%, was observed in the group of patients with
osteoarticular involvement. Regimens including doxycycline and streptomycin with or without rifampin
appeared more effective than other regimens in osteoarticular involvement.
Conclusions: In humans, brucellosis may lead to serious morbidity, and it continues to be a major health
problem in Turkey. There is no recommended treatment protocol for complicated brucellosis. Large
multicenter studies are needed to determine the most appropriate treatment choices and durations in
complicated brucellosis.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Brucellosis is a zoonosis caused by Gram-negative bacteria,
Brucella spp. The disease spreads to humans by the ingestion of raw
dairy products, the consumption of infected meat from domestic
livestock (sheep, goats, cattle, water buffalo, camels and pigs) and
close contact with their secretions and carcasses. High fever,
myalgia, and arthralgia of the large joints are the main symptoms.* Corresponding author. Tel.: +90 432 2164705; fax: +90 432 2167519.
E-mail addresses: mkarahocagil@yahoo.com, mkarahocagil@yyu.edu.tr
(M.K. Karahocagil).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.06.031Brucellosis usually causes abortion and sterility in animals, while it
may lead to a variety of clinical presentations, such as fever and
septicemia, and even multiple organ involvement, in humans.1,2
Because brucellosis is one of the great imitators in the world of
infectious diseases, it can mimic various multisystem diseases,
showing wide clinical polymorphism, which frequently leads to
misdiagnosis and treatment delays, further increasing the com-
plication rates.1,2 Clinically it may progress as a subclinical, acute,
subacute or chronic infection. Since Brucella spp are intracellular
bacteria, relapse is often seen.1–4
Human brucellosis remains the most common zoonotic disease
worldwide, with more than 500 000 new cases annually. Its
prevalence is more than 10/100 000 population in some endemicses. Published by Elsevier Ltd. All rights reserved.
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hyperendemic in the Mediterranean Basin and Arabian Peninsula,
India, Mexico, and Central and South America. Brucellosis has been
eradicated in England, in many northern European countries, and
in Australia, New Zealand, and Canada.5,6
In Turkey, brucellosis is common, especially in the Middle, East
and Southeast Anatolia regions.2,7 According to reports from the
Turkish Ministry of Health, 37 cases were reported in 1970, with
numbers rising to 18 408 cases in 2004 (incidence rate 25.67/100
000).2,8 It is thought that this increase is a result of improvements
in diagnosis and increased reporting, rather than a real increase in
the prevalence of the disease.
The aim of this study was to report our brucellosis cases, which
represent the largest series in the literature, and to compare our
epidemiological, clinical, and laboratory ﬁndings and therapeutic
features with reports of other large series.
Materials and methods
A total of 1028 brucellosis cases admitted to our clinic, the
Department of Infectious Diseases and Clinical Microbiology of
Yuzuncu Yil University Hospital, over a 10-year period from
January 1998 to September 2007, were included in the study. A
retrospective study was undertaken and patient ﬁles were
investigated for their history, clinical and laboratory ﬁndings, as
well as clinical outcomes and complications.
Brucellosis was diagnosed on the basis of one of the following
criteria: (1) isolation of Brucella spp in blood, bone marrow, or
cerebrospinal ﬂuid (CSF) and other body ﬂuids or tissue
samples; (2) a compatible clinical picture, such as arthralgia,
fever, sweating, chills, headache, and malaise, supported by the
detection of speciﬁc antibodies at signiﬁcant titers and/or the
demonstration of an at least four-fold rise in antibody titer in
serum specimens taken over 2 or 3 weeks. Signiﬁcant titers were
those determined to be 1/160 in the standard tube agglutina-
tion test (STA).9 An adequate response to anti-brucellosis
therapy was also accepted for diagnosis in those who were
seronegative and showed no growth of Brucella. Brucella abortus
M101 (Cromatest, Linear Chemicals, Spain) or B. abortus S99
antigens (Pendik Veterinary Control and Research Institution,
Istanbul, Turkey) were used for the STA. Serologic tests were all
carried out according to previously described techniques.
Screening was done by slide agglutination or Rose Bengal plate
agglutination test (Pendik Veterinary Control and Research
Institution, Istanbul).10
Cases were divided into three groups according to their
history, symptoms, and clinical presentation time: acute
brucellosis (0–2 months), subacute brucellosis (2–12 months),
and chronic brucellosis (>12 months). All cases underwent
routine laboratory tests. Blood, bone marrow, CSF, arthrocent-
esis ﬂuid, and abscess cultures were taken from patients
depending on their clinical ﬁndings. Up until December 2004,
cultures were identiﬁed by automated culture identiﬁcation
system, BACTEC 9240 (Becton–Dickson Diagnostic Instrument
System, Franklin Lakes, NJ, USA); after that time the Phoenix
Diagnostic System (Sparks, MD, USA) was used. The isolates
were identiﬁed by CO2 requirement, H2S production, urease and
oxidase positivity, growth in thionine, and positive agglutina-
tion with speciﬁc antiserum (Pendik Veterinary Control and
Research Institution, Istanbul, Turkey).11,12
Radiologic examinations, such as plain X-ray, ultrasound (USG),
computerized tomography (CT), magnetic resonance imaging
(MRI), and echocardiography were done when needed for
investigating the complications. A cranial CT was done for all
neurobrucellosis cases, while electroencephalography (EEG) was
done only in those whose encephalitis ﬁndings were dominant.Deﬁnitions
‘Focal form or complication’ was deﬁned as the presence of
symptoms or physical signs of infection at a particular anatomic
site in a patient with active brucellosis.
‘Osteoarticular involvement’ was considered when there were
inﬂammatory signs (heat, redness, pain, swelling, or functional
disability) in any peripheral joint, or when there was unrelieved
pain at rest together with radiological alterations and/or radio-
nuclide uptake in any deep joint, evaluated independently by both
the clinician and the radiologist.
‘Neurobrucellosis’ was deﬁned as: isolation of Brucella spp from
CSF of patients with suspected ﬁndings for brucellosis; or isolation
of Brucella spp from bonemarrow or blood cultures of patientswith
abnormal CSF ﬁndings; with or without STA positivity of any titer
in CSF with abnormal ﬁndings.
‘Hepatic involvement’ was deﬁned as a ﬁve-fold increase (>200
IU/l) in aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) levels without any other etiologic explanation,
and/or total bilirubin levels of over 2.5 g/dl.
‘Hematologic involvement’ was deﬁned as hematologic
abnormalities in laboratory and clinical ﬁndings (epistaxis,
bleeding, petechiae, purpura, disseminated intravascular coagula-
tion (DIC), and thrombophlebitis), excluding asymptomatic or
poorly symptomatic cytopenias or coagulation disturbances.
‘Relapse’ was deﬁned as the reappearance of symptoms or a
positive blood culture after the treatment was concluded.13
Treatment and follow-up
Patients were treated with various combinations of antibiotics.
The regimens included the following: oral doxycycline (100 mg
every 12 h), oral rifampin (300 or 600 mg every 24 h), intramus-
cular streptomycin (1 g every 24 h), oral ciproﬂoxacin (500 mg
every 12 h), and co-trimoxazole (80/400 or 160/800 every 12 h). In
neurobrucellosis patients and pregnant women, intravenous
ceftriaxone (2 g per day) was added to the regimen initially for
2–4 weeks, and other antimicrobials were given for at least 6
weeks. When required, the duration of therapy was extended and
data were recorded.
All patients were followed up for at least 2–3 weeks during
hospitalization. Outpatients were called for control visits at 2-
week intervals. At the control visits, complete blood count, C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR), and
liver enzymes were examined. In addition, STA was performed
after a one-month interval. All patients were followed up for at
least 6 weeks after completing therapy. After the treatment period,
patients were recalled for the ﬁrst control visit twoweeks later and
then at 6, 10 and 14 weeks, 6 months, and 1 year later. At the ﬁrst
control visit, complete blood count, CRP, ESR, and liver enzymes
were examined and STA performed. These tests were repeated at
each further control visit until full recovery. During the follow-up
period, blood cultures were only performed in those cases that
were assumed to be relapsed cases.
Results
Of the total 1028 patients, 539 (52.4%) were female and 489
(47.6%) were male. The mean patient age was 33.7  16.34 years,
ranging from3 to 81 years; 36 (3.5%)were aged 3–12 years, while 298
(29.0%) were aged 13–24 years, 251 (24.4%) were aged 25–34 years,
166 (16.1%) were aged 35–44 years, 125 (12.2%) were aged 45–54
years, 131 (12.7%) were aged 55–67 years, and 21 (2.0%) were over 67
years of age.
Of the cases, 435 (42.3%) had a history of raising livestock, while
26 (2.5%) had other occupations carrying a risk for brucellosis (13
Figure 1. Seasonal distribution of cases.
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workers, and four laboratory technicians). Of the cases, 55.2% were
found to have no occupational risk for brucellosis. Six hundred and
ﬁfty-four of the cases (63.6%) had a history of consumption of raw
milk and dairy products. There was a family history of brucellosis
in 17.8% of the cases. Thirty-one (3.0%) cases had none of the risk
factors for brucellosis.
With regard to clinical ﬁndings, 633 (61.6%) cases were
evaluated as acute, 222 (21.6%) as subacute, and 140 (13.6%) as
chronic, while 33 (3.2%) were evaluated as relapse cases. In terms
of gender distribution, 333 acute cases (52.6%), 117 subacute cases
(52.7%), 71 chronic cases (50.7%), and 18 relapse cases (54.5%)were
female.
The seasonal distribution of cases is shown in Figure 1. While
acute cases were seen intensively in spring (30.6%), subacute cases
were mainly seen in the autumn (33.8%). There were peaks for
acute cases in May and September.Table 1
Symptoms and ﬁndings of the cases according to clinical type
Acute brucellosis
(N=633)
Subacute brucellosis
(N=222)
n % n %
Symptom
Arthralgia 472 74.5 167 75.2
Fever 487 76.9 146 65.7
Fatigue 457 72.2 164 73.9
Sweating 425 67.1 141 63.5
Lack of appetite 331 52.3 108 48.6
Weight loss 268 42.3 103 46.4
Myalgia 238 37.6 105 47.3
Chills 292 46.1 48 21.6
Upper back pain 52 8.2 13 5.9
Lower back pain 146 23.1 39 17.6
Nausea/vomiting 167 26.4 63 28.4
Abdominal pain 48 7.6 15 6.8
Headache 119 18.8 22 9.9
Cough 17 2.7 4 1.8
Epistaxis 8 1.3 0 0
Scrotal pain 24 3.8 10 4.5
Findings
Fevera 233 36.8 58 26.1
Hepatomegaly 142 22.4 47 21.2
Splenomegaly 102 16.1 29 13.1
Hepatosplenomegaly 79 12.5 16 7.2
Lymphadenopathy 15 2.4 6 2.7
Stiff neck 43 6.8 8 3.6
Peripheral arthritis 93 14.7 39 17.6
Spondylitis 8 1.3 12 5.4
Sacroiliitis 32 5.1 19 8.6
Endocarditis 5 0.8 2 0.9
Skin lesion 15 2.4 7 3.2
Icterusb 14 2.2 1 0.5
Scrotal swelling 24 3.8 10 4.5
a Fever: 38 8C.
b Icterus: total bilirubin 2.5mg/dl.The most frequent symptoms were arthralgia (73.7%), fever
(72.2%), and fatigue (71.2%). The most frequent clinical ﬁndings
were fever (28.8%), hepatomegaly (20.6%), splenomegaly (14.5%),
and peripheral arthritis (14.3%) (Table 1).
In a comparison of those in the 3–14 years age group and adults,
mostof the cases (89.7%)wereacute andsubacute. Therewere fewer
chronic cases in children (four cases) than in adults (5.1% vs. 14.3%),
however the numbers of relapsing cases (four cases) were similar
(5.1%vs. 3.1%). The seasonal distribution of acute and subacute cases
was similar in bothgroups. In children, themost frequent symptoms
were arthralgia (85.9%), fever (71.8%), fatigue (55.1%), sweating
(50%), loss of appetite (37.2%), and weight loss (35.9%). Abdominal
pain occurred more frequently than in the adult group (25.6% vs.
6.7%), while myalgia occurred less frequently (17.9% vs. 36.1%). The
most frequent clinical and laboratory ﬁndings in children were
anemia (47.4%), fever (28.2%), peripheral arthritis (21.8%), hepato-
megaly (17.9%), leukopenia (15.4%), and splenomegaly (14.1%).
Peripheral arthritisoccurredmore frequently than intheadultgroup
(21.4% vs. 14.3%), while sacroiliitis was less frequent (2.6% vs. 6.2%)
and spondylitis was not seen.
The most common laboratory ﬁndings were high CRP levels
(58.4%), high ESR (51.3%), and anemia (40.3%). The STA test was
positive in 967 (94.1%) cases, with titers ranging from 1/160 to 1/
163 840. Forty-nine cases (4.8%) who had a negative STA were
found to be positive by Coombs STA. Twelve cases (1.2%) were
seronegative; six of these showed Brucella spp growth in their
cultures and the remaining six were diagnosed following a good
response to anti-Brucella therapy (clinical and laboratory ﬁndings,
especially ESR and CRP improved). These cases remained
seronegative on at least three occasions during the follow-up
period; they were then lost to follow-up.Chronic brucellosis
(N=140)
Relapse brucel-
losis (N=33)
Total brucellosis
(N=1028)
n % n % n %
94 67.1 25 75.8 758 73.7
90 64.3 19 57.6 742 72.2
87 62.1 24 72.7 732 71.2
79 56.4 21 63.6 666 64.8
48 34.3 17 51.5 504 49.0
53 37.9 12 36.4 436 42.4
18 12.9 10 30.3 371 36.1
0 0 8 24.2 348 33.9
3 2.1 2 6.1 70 6.8
27 19.3 6 18.2 218 21.2
18 12.9 8 24.2 256 24.9
5 3.6 1 3.0 69 6.7
5 3.6 2 6.1 148 14.4
0 0 0 0 21 2.0
0 0 0 0 8 0.8
1 0.7 0 0 35 3.4
0 0 5 15.2 296 28.8
19 13.6 4 12.1 212 20.6
15 10.7 3 9.1 149 14.5
10 7.1 1 3.0 106 10.3
4 2.9 0 0 25 2.4
0 0 0 0 51 5.0
12 8.6 3 9.1 147 14.3
12 8.6 0 0 32 3.1
7 5 6 18.2 64 6.2
0 0 0 0 7 0.7
3 2.1 0 0 25 2.4
0 0 1 3.0 16 1.6
1 0.7 0 0 35 3.4
Table 2
Laboratory ﬁndings of the cases according to clinical type
Acute brucellosis
(N=633)
Subacute brucello-
sis (N=222)
Chronic brucello-
sis (N=140)
Relapse brucel-
losis (N=33)
Total brucellosis
(N=1028)
n % n % n % n % n %
Non-speciﬁc laboratory ﬁndings
Anemiaa 278 43.9 88 39.6 39 27.9 9 27.3 414 40.3
Leukopeniab 97 15.3 13 5.9 1 0.7 1 3.0 112 10.9
Leukocytosisb 60 9.5 19 8.6 10 7.1 4 12.1 93 9.0
Thrombocytopeniac 75 11.8 14 6.3 6 4.3 3 9.1 98 9.5
Pancytopenia 44 7.0 4 1.8 1 0.7 1 3.0 50 4.9
Lymphomonocytosisd 165 26.1 74 33.3 43 30.7 8 24.2 290 28.2
ESR 20–40mm/h 182 28.8 81 36.5 46 32.9 17 51.5 326 31.7
ESR >40mm/h 129 20.4 38 17.1 31 22.1 3 9.1 201 19.6
Transaminase elevatione 198 31.3 36 16.2 18 12.9 3 9.1 255 24.8
Bilirubin elevationf 66 10.4 6 2.7 0 0 2 6.1 74 7.2
CRP positive 417 65.9 117 52.7 48 34.3 18 54.5 600 58.4
RF positive 22 3.5 6 2.7 7 5 4 12.1 39 3.8
Speciﬁc laboratory ﬁndings
STA positive 601 94.9 199 89.6 134 95.7 33 100 967 94.1
Coombs STA positive 26 4.1 19 8.6 4 2.9 0 0 49 4.8
Seronegative cases 6 0.9 4 1.8 2 1.4 0 0 12 1.2
Culture positive/culture taken cases 125/284 44.0 32/87 36.8 5/18 27.8 1/7 14.3 163/396 41.2
Culture positive/all cases 125/633 19.7 32/222 14.4 5/140 3.6 1/33 3.0 163/1028 15.9
Blood 95 15.0 19 8.6 2 1.4 1 3.0 117 11.4
Bone marrow 16 2.5 8 3.6 2 1.4 0 0 26 2.5
Other 14 2.2 5 2.3 1 0.7 0 0 20 1.9
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; STA, standard tube agglutination.
a Anemia: female 12g/dl and male 13.5 g/dl.
b Leukopenia: <4109/l; leukocytosis: >11109/l.
c Thrombocytopenia: <150109/l.
d Relative lymphomonocytosis.
e Alanine aminotransferase (ALT): 50 IU/l and aspartate aminotransferase (AST): 50 IU/l.
f Bilirubin elevation: total bilirubin 1.5mg/dl.
Table 3
Focal involvement of the cases according to clinical type
Involvement type Acute brucellosis
(N=633)
Subacute
brucellosis
(N=222)
Chronic
brucellosis
(N=140)
Relapse
brucellosis
(N=33)
Total
brucellosis
(N=1028)
n % n % n n % n % n
Osteoarticular 138 21.8 77 34.7 36 25.7 9 27.3 260 25.3
CNS 49 7.7 8 3.6 1 0.7 0 0 58 5.6
Epididymo-orchitis 24 3.8 10 4.5 1 0.7 0 0 35 3.4
Liver 23 3.6 4 1.8 0 0 1 3.0 28 2.7
Skin 15 2.4 7 3.2 3 2.1 0 0 25 2.4
Hematologic 13 2.1 4 1.8 0 0 0 0 17 1.7
Cardiovascular 5 0.8 2 0.9 0 0 0 0 7 0.7
Pleurisy 5 0.8 2 0.9 0 0 0 0 7 0.7
Peritonitis 2 0.3 3 1.4 0 0 0 0 5 0.5
Soft tissue 2 0.3 1 0.5 0 0 0 0 3 0.3
Kidney 2 0.3 0 0 0 0 0 0 2 0.2
Retinitis 1 0.16 0 0 0 0 0 0 1 0.1
Thyroiditis 1 0.16 0 0 0 0 0 0 1 0.1
Prostatitis 1 0.16 0 0 0 0 0 0 1 0.1
Pancreatitis 1 0.16 0 0 0 0 0 0 1 0.1
Patients with focal involvement 225 35.5 97 43.7 40 28.6 9 27.3 371 36.1
CNS, central nervous system.
Some of the patients had more than one focal involvement.
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appropriate cultures were taken. Of these, 117 were from blood
(71.8%), 26 from bonemarrow (16.0%), three from CSF (1.8%), eight
from joint ﬂuid (4.9%), four from abscess material (2.5%), three
from paracentesis ﬂuid (1.8%), one from thoracentesis ﬂuid (0.6%),
and one from ejaculate (0.6%). Isolation was achieved from 117 of
298 blood cultures (39.3%), 26 of 47 bonemarrow cultures (55.3%),
and 20 of 51 cultures from other sites (39.2%). The lowest growth
rate was seen in CSF with 10.7%. Typing was possible for only 83
isolates, yielding Brucella melitensis. Table 2 summarizes the
laboratory ﬁndings of the cases.Focal involvement was present in 371 (36.1%) cases (Table 3).
The most frequent involvement was osteoarticular involvement
with 260 cases (25.3%). Osteoarticular involvement included
peripheral arthritis (56.5%), sacroiliitis (24.6%), spondylitis
(12.3%), and paraspinal abscess (3.5%). Monoarthritis was seen
in 50 patients, while polyarthritiswas found in 97 cases. Sacroiliitis
was unilateral in 51 and bilateral in 13 cases.
Laboratory abnormalities with regard to the hematologic
system were present in 452 cases (44.0%), but the rate of clinically
affected patients was much lower at 1.7% (seven cases with
petechiae and purpura, six cases with epistaxis, two cases with
Table 4
Initial therapeutic regimens, follow-up patients, and results according to patient groups
Treatment regimens according patients Number of cases Follow-up patients Relapse, n (%)
Osteoarticular involvementa 255b 141 12 (8.5)
Doxycycline + rifampin 62 35 4 (11.4)
Doxycycline + streptomycinc 81 41 3 (7.3)
Doxycycline + rifampin+ streptomycinc 95 53 3 (5.7)
Ciproﬂoxacin +doxycycline or rifampin 17 12 2 (16.7)
Neurobrucellosisd 58 49 –
Doxycycline + rifampin+ ceftriaxonee 39 34 –
Rifampin+Doxycycline + co-trimoxazole 9 7 –
Rifampin+Doxycycline + streptomycinc 10 8 –
Other patientsf 715 346 13 (3.8)
Doxycycline + rifampin 193 72 3 (4.2)
Doxycycline + streptomycinc 137 57 2 (3.5)
Doxycycline + rifampin+ streptomycinc 103 61 2 (3.3)
Doxycycline + rifampin+ levamisoleg 72h 43 1 (2.3)
Doxycycline + rifampin+ streptomycinc + levamisoleg 53h 36 –
Doxycycline + ciproﬂoxacin 44 22 1 (4.5)
Rifampin+ co-trimoxazole 33 15 –
Rifampin+ ciproﬂoxacin 27 11 1 (9.1)
Other regimeni 53 29 3 (10.3)
a Treatment duration 6–12 weeks.
b Pregnant women and patients under 8 years of age excluded.
c For 4–21 days.
d Treatment duration 12–24 weeks.
e For 21–30 days.
f Treatment duration 6–12 weeks.
g For 6 weeks, 80mg every other day.
h Only chronic cases and treatment duration 12–24 weeks.
i For pregnant women and children <8 years of age.
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thrombophlebitis).
Central nervous system (CNS) involvement was present in 58
cases (5.6%). Of these, seven had encephalitis (12.1%), two had
myelitis (3.4%), two had polyradiculoneuritis (3.4%), one had a
hypophysis abscess (1.7%), and one had a frontal abscess (1.7%).
The remaining 45 patients had either meningitis or meningoence-
phalitis (77.6%). Four patients had toxic febrile neurobrucellosis
and one had status epilepticus.
Genitourinary system involvement was present in 38 (3.7%)
patients, mainly presenting as epididymo-orchitis with 35 cases
(3.4%), being bilateral in three cases. Three of the unilateral cases
required orchiectomy because of testicular abscess formation. One
patient had prostatitis, and Brucella sppwere isolated from semen.
In terms of renal involvement, we detected one patient with
tubulo-interstitial nephritis and one with glomerulonephritis and
endocarditis at the same time. Seventeen of our cases were
pregnant (1.7%). None of themhad amiscarriage or abortion during
follow-up.
Elevated transaminase levels were detected in 24.8%, while
hepatic involvement was present in only 28 patients (2.7%).
Twenty-ﬁve patients (2.4%) had skin involvement; 13 had a
maculopapular-urticarial rash, nine had petechiae–purpura, and
three had erythema nodosum. Seven patients had cardiovascular
involvement (0.7%), all with endocarditis. One of the patients had
renal failure, followed by a secondary infection and later died,
while another died because of chordae tendineae rupture with
acute cardiac failure. Three patients were lost to follow-up and two
others underwent cardiac surgery. Two patients died because of
endocarditis and the third died because of neurobrucellosis with
delayed admission to hospital.
Various initial regimenswere administered to the 1028 patients
with brucellosis. Only 536 patients were followed up for one year.
The treatment regimens and relapse rates are given in Table 4.
Ceftriaxone and co-trimoxazole were added to the regimen of
patients diagnosed with neurobrucellosis or in the case of
pregnancy. Patients having no nervous system or osteoarticular
involvement were given various regimens. The treatment durationwas 6–12 weeks in osteoarticular involvement, 12–24 weeks in
neurobrucellosis, and 6–12 weeks for the other clinical forms. In
chronic patients, levamisole was added (6 weeks, 80 mg every
other day) and the treatment duration was extended to 12–24
weeks. The overall relapse rate in patients with brucellosis was
4.7%. The relapse rate in patients with osteoarticular involvement
was higher than that of patients with other involvements (8.5% vs.
3.7%).
Discussion
Brucellosis is the most frequent zoonotic infectious disease in
the world, affecting more than 500 000 people each year.5 The ﬁrst
systematic study of the epidemiology of brucellosis in Turkish
patients was performed by C¸etin et al. between 1984 and 1987. In
this multicenter study, more than 70 000 subjects were
investigated for Brucella seropositivity, revealing 6% seropositivity
in the high-risk population and 1.8% in the entire study
population.14 Among high-risk patients in the eastern part of
Turkey, seropositivity has been reported to be as high as 27.2%.15
However, the true rates of brucellosis in endemic countries are
most probably higher than reported due to deﬁciencies in its
diagnosis or recording.16
In endemic countries, brucellosis ismore prevalent in the 15–35
years age group.1,2 In the present study 53.4% of patients were
between 13 and 34 years of age. Some epidemiological studies
from Turkey have reported relatively younger ages compared to
studies from outside Turkey. This may be attributed to involve-
ment in the raising of livestock starting at a younger age in our
country.17,18 On the other hand, some studies from Turkey and
outside Turkey have reported higher mean ages.13,19–22 In a recent
study by Gu¨l et al. from Turkey, a mean age of 27  3.6 years was
reported in a population comprising 80.7% male and 19.3% female.23
The differences between these results could be explained by the
diversity of populations, because the latter study was performed in a
military hospital.
Brucellosis may appear in four different forms, namely acute,
subacute, chronic, and relapse.1–3 In our study, the acute
Table 5
Comparison of gender, age, and clinical types of brucellosis in various studies
Author [Ref.] Country No. of cases Female % Male % Mean age, years Acute
brucellosis (%)
Subacute
brucellosis (%)
Chronic
brucellosis (%)
Akdeniz et al. [24] Turkey 233 54 46 29.1a; 35.2b 58.3 14.2 27.5
Aygen et al. [20]c Turkey 480 55.2 44.8 44.116.4 67.1 25.2 5
Gu¨r et al. [17] Turkey 283 49 51 32.6914.39 25 59 16
Ko¨kog˘lu et al. [25] Turkey 138 48.5 51.5 32.214.1 57.2 16.7 26.1
Savas¸ et al. [21] Turkey 140 72.9 27.1 45.8115.62 53.6 21.4 25
Demirog˘lu et al. [22] Turkey 151 58.9 41.1 45.416 66.2 23.9 9.9
Roushan et al. [19] Iran 469 43.1 56.9 36.9715 54.4 38.2 7.4
Lulu et al. [36] Kuwait 400 37 63 33 77 12.5 10.5
Mantur et al. [39] India 495 21.2 78.8 31d 62.6 29.5 7.9
Present study Turkey 1028 52.4 47.8 33.7016.34 61.6 21.6 13.6
a Male.
b Female.
c Asymptomatic patients 2.7%.
d Accounted for 390 of the cases.
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subacute and chronic cases constituted 21.6% and 13.6% of the
cases, respectively; this is in accordance with previous reports
(Table 5). Although Akdeniz et al.24 have reported a higher rate
(27.5%) in our region, the chronic infection rate of 13.6% in our
study is higher than that of some previous reports, which can be
explained by treatment failure or hyperendemicity in our region.
However, certain studies have also reported higher incidences of
chronic or subacute infections.17,21,25
The primary transmission route of brucellosis is by the
ingestion of unpasteurized dairy products in endemic countries,
whereas in developed countries infection occurs mostly due to
occupational exposure.1–3 In our geographic region – the Lake Van
basin – the most common route of spread is the consumption ofTable 6
Comparison of symptoms and signs in various studies
Author [Ref.]
Akdeniz
et al. [24]
Ko¨kog˘lu
et al. [25]
Aygen
et al. [
Country Turkey Turkey Turkey
Number of cases 233 138 480
Symptoms %
Fever 73 78.3 79.8
Sweating 72.5 84.4
Fatigue 71 71 90
Lack of appetite 50 57.2 41.3
Chills 44.2
Arthralgia 68 77.5 81.9
Nausea/vomiting 15 16.7/8.7 32.3/21
Headache 12 51.4 19
Lower back pain
Upper back pain 58.5
Abdominal pain 22 15.9 21
Myalgia 57 50.8 49.2
Weight loss 54 44.4
Testicular pain
Signs %
Fever 40.6 39
Splenomegaly 22 36.2 14.2
Hepatomegaly 34 26.8 21.3
Lymphadenopathy 6 9.4
Osteoarticular involvement 21 46.4 19
CNS involvement/stiff neck 2 3.6 6.5
Endocarditis/cardiovascular involvement 1 1.5 0.4
Skin lesion/rash 2 8.7 0.4
Peritonitis 0.4
Epididymo-orchitis/prostatitis/
genitourinary system involvement
5 7.5 1
a Excessive sweating.
b Constitutional symptoms: at least two of asthenia, lack of appetite, and fatigue.
c Neurological sign.regional herbaceous cheese produced from raw milk.15,24,26 A
history of raw dairy product consumption was present in 63.6% of
the cases in our study. In some epidemiologic studies from Turkey,
a history of raw dairy product consumption has been reported for
between 62.6% and 94.6% of cases.17,18,22,27–29 The consumption of
raw dairy products in other studies has been reported as occurring
in 23.6% of cases in Spain by Colmenero et al.,13 69% in Kuwait by
Mousa et al.,30 34.7% in the Balkan Peninsula by Bosilkovski et al.,31
and 22.4% in Iran by Roushan et al.19 A history of a local traditional
food – raw meat ball – consumption was reported in 55% in the
series of Gu¨r et al.17 and 57% in Kılıc¸ et al.32
In developed countries, most of the brucellosis cases occur due
to occupational exposure. High-risk occupations for the disease are
the raising of livestock, butchery, farming, and veterinary20]
Memish
et al. [38]
Mantur
et al. [39]
Mousa
et al. [30]
Colmenero
et al. [13]
Present
study
Saudi Arabia India Kuwait Spain Turkey
160 495 379 530 1028
91 90.5 72.2
19a 3.8 38.8 84.9 64.8
1.2 73b 71.2
25 49
49 38.7 86 33.9
66 23.6 21.1 50.1 73.7
.7 2.6 -/15 24.9
16 1.6 22.2 14.4
17.9 23.6 21.1
14.8 6.8
2.6 7 6.7
21.4 38.7 36.1
7 42.4
2.8 4.5 3.4
84 84.2 98.1 28.8
7 29 42.2 22.3 24.8
6 21.1 36.9 38.1 30.9
2.4 8.7 9.1 2.4
43 36.9 23 25.3
5 1.4 9.1c 5
2 1.2 0.7
1 3.4 2.4
0.5
2 2.2 22 3.7
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studies from Turkey, a history of livestock raising has been shown
for between 14.6% and 70.3% of cases,17,18,21,22,27,33–35 whereas a
history of livestock raising in other countries has been reported in
11.1% from Kuwait by Mousa et al.,30 9% also from Kuwait by Lulu
et al.,36 11.3% from Iran by Roushan et al.,19 and 20% fromGreece by
Andriopoulos et al.37 In our population, raising livestock was
evident for 42.3% of patients, which is in accordance with previous
reports from Turkey. Demirtu¨rk et al. reported 41.1% non-
occupational and 3% occupational contact with an animal.29
However in our region, most of the families, particularly house-
wives, deal with the raising of livestock, which increases the
contact rate in our study. Occupational contact was found in 26
patients in our study (2.5%; 13 veterinarians, nine slaughterhouse
workers, and four laboratory technicians). No contact history was
identiﬁed in 55.2% of patients. In previous reports, a family history
of brucellosis has been reported for between 12.6% and 43% of
cases in Turkey,17,22,27,35 and also in 9.6% in the study by Roushan
et al.19 from Iran. In our study, a family history was present in
17.8% of patients. This may be attributed to the concept of a larger
family in our region. In our study, 31 patients (3%) had no risk
factor for brucellosis. Risk factors in other studies have been found
for between 10.9% and 28.7% of cases,13,17,18,30,31 and even higher
rates have been reported (41.8% by Yu¨ce et al.35 and 56.7% by
Roushan et al.19).
Most brucellosis cases present in the spring and summer
months.1–3 Gu¨r et al reported that 68% of cases presented in the
spring and summer.17 Savas et al. observed the highest presenta-
tion in July and the lowest in January in their study.21 Lulu et al.36
reported that 78% of the cases were seen in the March–July period,
peaking in April–May. Roushan et al.19 reported that 25.2% of cases
occurred in spring, 40.1% in summer, 22% in autumn, and 12.8% in
winter months. In our study, 30.6% of acute cases presented in the
spring, whereas 33.8% of subacute cases presented in the autumn.
No seasonal difference was observed for chronic and relapsed
cases. Two peaks were observed in our study, the ﬁrst in April–
May, which could be due to the increased use of fresh cheese, and
the second in September, which could be due to the use of stored
cheese from the spring season. Similarly two previous studies from
the same region performed by Akdeniz et al.24 andGu¨r et al.,17 have
reported a second peak in September.
Typically acute brucellosis cases present with chills, fever,
fatigue, sweating, weight loss, and back pain.1,2 Subacute cases
show a protean clinical presentation, although with less severe
symptoms compared to the acute form. Patients with the chronic
form of the disease usually present with complaints of malaise,
nervousness, emotional lability, depression, or generalized mus-
culoskeletal pain.2,3 In our study population, most of the patients
complained of arthralgia, fever, and fatigue. In acute cases, fever
was observed in 76.9% of patients, arthralgia in 74.5%, and fatigue
in 72.2% of the patients. In subacute cases, arthralgia was reported
in 75.2% of the patients, and fatigue and fever were reported in
73.9% and 65.7% cases, respectively. In the chronic form, 67.1% of
cases had arthralgia, 64.3% had fever, and 62.1% had fatigue. In
relapsed cases, arthralgia was evident in 75.8% of cases; fatigue,
sweating, and fever were evident in 72.7%, 63.6% and 57.6% of
cases, respectively.
In our study, 72.2% of patients complained of fever, but it was
only evident as a clinical ﬁnding in 28.8%. These results are in
accordance with two previous studies, which reported fever as a
symptom in 78.3% but as a sign in 40.6% (Kokoglu et al.25) and as a
symptom in 79.8% vs. as a sign in 39% (Aygen et al.20). The studies
that reported a higher rate of fever as a clinical ﬁnding in
brucellosis are available in the literature.13,38,39 This difference
could be due to the administration of over-the-counter non-
steroidal anti-inﬂammatory drugs for relieving musculoskeletalpain. The typical undulant fever was observed rarely and most
patients with undulant fever were either late presentation or
untreated cases. A brief review of brucellosis symptoms obtained
from large epidemiologic studies is presented in Table 6.
Anemia, leukopenia, thrombocytopenia, elevated liver
enzymes, and increased CRP were the most prominent laboratory
abnormalities seen in acute and subacute cases. Increased ESR and
lymphomonocytosis were observed to the same extent in all forms.
Rheumatoid factor was found positive only in chronic cases and
relapses.1–3
Serology is the preferredmethod for the diagnosis of brucellosis
when bacterial isolation is not possible, and serologic testing is
widely used in the diagnosis of brucellosis.1–3 STA test positivity
was reported in 95% by Akdeniz et al.24 and in 87% by Tas¸ova et al.18
The STA test was positive in 94.1% of our study population. Coombs
STA test is preferred when the STA test is found negative. Coombs
STA test was positive in 4.8% of cases in our study, in accordance
with the previous report by Akdeniz et al. with 5%.24 Following
these tests, 1.1% of our patients remained seronegative. Demirog˘lu
et al. also reported 1.3% seronegativity in their study.22
In regions endemic for brucellosis such as ours, serological test
results should only be interpreted as signiﬁcant in the presence of
clinical ﬁndings compatible with brucellosis, and in suspect cases,
treatment should be delayed until various serologic tests have
been performed (Coombs test, 2-mercaptoethanol (2-ME) agglu-
tination test, Brucellacapt, ELISA) during the follow-up of the cases.
A deﬁnite diagnosis of brucellosis relies on isolation of the
bacteria from blood, bone marrow, or from other tissue cultures.
The reported bacterial isolation rates in the literature range from
15% to 90% depending on the methodology used.1,2 Previous
antibiotic use signiﬁcantly decreases the likelihood of bacterial
isolation in blood cultures in chronic cases.20,40 Bone marrow
cultures may provide a higher sensitivity, yield faster culture
times, and may be superior to blood cultures when evaluating
patients with previous antibiotic use.41,42 In our study, culture
positivitywas higher in acute cases (44.0%) than in the other forms.
Isolation of bacteria from bone marrow was achieved in 55.3% of
patients, but CSF had the lowest isolation rate (10.7%). A brief
summary of laboratory abnormalities reported in other epide-
miologic studies is presented in Table 7.
Brucella infection may involve any organ or tissue in the body.
Organ involvement can be assigned as focal involvement or as a
complication. The most common systems affected are the
locomotor, gastrointestinal, genitourinary, hematologic, cardio-
vascular, respiratory, and central nervous systems.1,2 Focal
involvement rates of between 27.7% and 43.2% have been
reported.13,20,33,35 In our study, focal involvement was observed
in 36.1% of cases. Focal involvement characteristics in the large
epidemiologic studies are reviewed in Table 8.
Osteoarticular involvement occurs in 20–85% of cases.1,2
Osteoarticular involvement rates of between 58.8% and 79.5%
have been reported,17,22,43,44 but lower rates of between 9.3% and
22.8% have also been reported.20,45–48 In our study, osteoarticular
involvement was observed in 21.8% of acute cases, 34.7% of
subacute cases, 25.7% of chronic cases, and in 27.3% of relapsed
cases, with an overall rate of 25.3%, similar to that found by
Akdeniz et al.24 (21% of the total cases). The enormous range
between reports in the literature may be due to characteristics of
the study populations, the radio-diagnostic methods used, and the
different diagnostic criteria employed. The rate of osteoarticular
involvement in childrenwas 24.4%, similar to the rate in adults, but
most of them presented as peripheral monoarthritis.
As the largest organ of the reticuloendothelial system, the liver
is affected in almost all patients with brucellosis. Liver involve-
ment results in mild to moderate elevation in liver enzymes.1,2 On
the other hand, all cases with elevated liver enzymes should not be
Table 7
Comparison of laboratory ﬁndings in various studies
Author [Ref.]
Akdeniz
et al. [24]
Aygen
et al. [20]
Demirog˘lu
et al. [22]
Lulu
et al. [36]
Roushan
et al. [19]
Colmenero
et al. [13]
Present study
Country Turkey Turkey Turkey Kuwait Iran Spain Turkey
Number of cases 233 480 151 400 469 530 1028
Anemia 55 54.6 51.7 7 15.1 48.1 40.3
Leukopenia 21 7.7 6.6 19 3 28.7b 10.9
Leukocytosis 6.5 9 12.2 5.5c 9
Thrombocytopenia 26 13.7 2 12 3.4 14.4e 9.5
Pancytopenia 8 3.5 6 4.9
Lymphomonocytosis 40 68.3a 44.4 41 92.1f 28.2
ESR >20mm/h 61 58.8 61.6 77 77.8 66.8 31.7
ALT/AST elevations (50 IU/l) 15 15.2g 40/54 49.8/50.6 24.8
CRP positive (>6mg/l) 36 59.6 59.1 58.4
RF positive 4 8.5 3.8
STA positive (1/160) 95 98.7 510 94.1
Coombs STA positive 5 4.8
STA positive (total) 91.7 527 98.9
Seronegative cases 1.3 1.2
Culture positive 53 45 68 30 15.9d
Blood 48 41.1 51.2 68.8 11.4d
Bone marrow 61 43.5 1 2.5d
CSF 20 35.5 1 0.3d
Joint ﬂuid 45.5 1 1 0.8d
Other 1 case 4 cases 1 case 9 cases
ESR, erythrocyte sedimentation rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; RF, rheumatoid factor; STA, standard tube
agglutination; CSF, cerebrospinal ﬂuid.
a 45%.
b <4.5109/l.
c >10109/l.
d According to total cases.
e <130109/l.
f >1109/l.
g ALT >70 IU/l.
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reported in the literature in around 2–3%.13,17,43 Lulu et al. reported
40% hepatic involvement in their study, namely 1% clinical
hepatitis and 38.5% anicteric hepatitis.36 In our study, liver enzyme
elevation was observed in 24.8% of the cases and a diagnosis of
clinical hepatitis was made in only 2.7% of cases.
Neurobrucellosis occurs in less than 5% of brucellosis patients.
Neurological manifestations of the disease are frequently menin-
gitis or meningoencephalitis.1,2 Although bacterial isolation was
not possible in most cases, CNS involvement was reported at
between 1.3% and 2%.13,18,24 In our study, 5.6% of cases were
diagnosed with neurobrucellosis, which is consistent with most
reports from Turkey and Spain. Among these reports, the Brucella
recovery rate has been reported at between 6% and 7% inTable 8
Systems involvement and rates in brucellosis in various studies
Author [Ref.] Country No. of
cases
Osteoarticular Hematological
Aygen et al. [20] Turkey 480 19
Gu¨r et al. [17] Turkey 283 69 4t+pan+ha
Ertek et al. [43] Turkey 216 68.1 2.8t+pan
O¨rmen et al. [33] Turkey 104 23
Gu¨l et al. [23] Turkey 140 41
Demirog˘lu et al. [22] Turkey 151 33.7
Colmenero et al. [13] Spain 530 21.3 6pan, 2dic cases
Roushan et al. [19] Iran 469 28.6
Mantur et al. [39] India 495
Barroso Garcia et al. [48] Spain 890 22.8 9.9ep,*
Present study Turkey 1028 25.3 1.7
GUS, genitourinary system; CNS, central nervous system.
br, bronchitis; car, carditis; dep, depression; dic, disseminated intravascular coagulation;
glomerulonephritis; h, hepatitis; ha, hemolytic anemia; ih, icteric hepatitis; la, liver absc
pn, pneumonia; pr, prostatitis; py, pyelonephritis; pz, pleurisy; sjs, Stevens–Johnson syn
* In 565 cases.CSF.17,20,49,50 This high incidence of neurobrucellosis in our report
may be due to referral of this particular group to our clinic, while
cases with other organ involvement could be managed at other
clinics. The fact that one of our cases died because of neuro-
brucellosis with delayed admission emphasizes the serious and
possibly fatal outcome of the situation and the value of early
admission, diagnosis, and treatment in neurobrucellosis.
Urogenital involvement occurs in 2–10% of patients, with
unilateral epididymo-orchitis as the most common presenta-
tion.1,2 In our study, 3.4% of patients had epididymo-orchitis,
which is in accordance with previous reports.13,17,22–24,33,43
Epididymo-orchitis was present in 3.8% of acute, in 4.5% of
subacute, and in 0.7% of chronic cases. Brucella spp grew in the
ejaculate of one patient with prostatitis. Colmenero et al.13Cardiovascular Respiratory
system
GUS Skin Liver CNS
0.4end 1pn case 1eo+pr 0.4 6.5
2car cases 5pn+br+pz 8eo+py+pr 17sr 3h cases 7
2.3end 5.5eo 4.2sr+en 3.2h 4.2
1.9end 6.5pn 3.8eo 0.9
6eo 3 7
5.3eo+pr+uti 0.7 6
1.5end+my+p 1 case 5.1eo+pr 3.8 2.5h+la 1.7
0.6end 6.2eo 2en cases 1ih case 1 case
1.2end 1pn+br 2.8eo+h+uti 1sr+sjs 1.4
0.7car+phl 0.5 6.9eo+m 4.5 4.2
0.7 0.7pz 3.4eo+pr, 0.2gn 2.4 5.6
en, erythema nodosum; end, endocarditis; ep, epistaxis; eo, epididymo-orchitis; gn,
ess; m, mastitis; my, myocarditis; p, pericarditis; pan, pancytopenia; phl, phlebitis;
drome; sl, skin lesion; sr, skin rash; t, thrombocytopenia; uti, urinary tract infection.
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and one case with both epididymo-orchitis and prostatitis.
Renal involvement is a rare manifestation of brucellosis.
Glomerulonephritis and tubulointerstitial nephritis have been
reported in some case reports.1,2 In our study, one patient
presented with tubulo-interstitial nephritis and another with
pyelonephritis and endocarditis. The latter case progressed to
chronic renal failure and subsequently died. In our opinion, renal
involvement may occur more frequently than previously thought
in brucellosis, and may be under-diagnosed in nephrology clinics.
Less than 5% of brucellosis patients exhibit non-speciﬁc skin
symptoms, such as erythema, papules, petechiae, urticaria,
impetigo, eczematous rash, erythema nodosum, subcutaneous
abscess, and cutaneous vasculitis.1,2 Skin involvement has been
reported in 0.7–17% of cases.17,22–24,43 In our study, skin
involvement was observed in 2.4% of acute, in 3.2% of subacute,
and in 2.1% of chronic cases, with an overall rate of 2.4%. The
difference among reports could be due to the non-speciﬁc nature of
skin lesions.
Although hematological involvement is frequent in brucellosis,
most of these cases are mild, and serious clinical disease is rare.
Ertek et al. reported 2.8% hematological involvement in their
study.43 Disseminated intravascular coagulation was reported in
two cases by Colmenero et al.13 and one case each by Akdeniz
et al.24 and Al-Eissa et al.51 Additionally Al-Eissa et al. reported four
cases of acute hemolysis.51 Ertek et al.43 reported 0.9% throm-
bophlebitis in their series. In our study, hematologic involvement,
when taking into account laboratory abnormalities, was observed
in 452 patients (44.0%), whereas when taking into consideration
clinical ﬁndings related to hematological involvement, serious
clinical disease was only observed in 17 patients (1.7%). None of
the patients had hemolysis in our study, but this is probably
because these cases may have been followed up at the hematology
clinics.
Endocarditis is the most common presentation of cardiovas-
cular involvement, which is reported in less than 2% of patients.1,2
Akdeniz et al.24 reported an incidence rate of 1% in their study.
Cardiovascular involvement rates in large epidemiological studies
are reported at between 1% and 2.3%.13,17,24,33,43 In our study, seven
patients had endocarditis. Five of them had the acute form and the
other two the subacute form of the disease. This low rate (0.7%)
may be as a result of patients being followed up at the cardiology
clinic at the same time.
Despite treatment including several antibiotic regimens,
relapse is estimated to occur in 5–40% of patients with acute
brucellosis in the following year, depending on antibiotic use,
duration of treatment, and drug combination.52 In this study, the
patients were given various regimens. The treatment duration was
based on organ involvement, CRP and ESR normalization. The
relapse rate of all patients with brucellosis was 4.7%. The highest
relapse rate, 8.5%, was observed in the group of patients with
osteoarticular involvement.
The doxycycline plus streptomycin regimen could prove to be
more effective than the doxycycline plus rifampin regimen in
patients with spondylitis.53,54 In our study, the doxycycline plus
streptomycin regimen and the doxycycline plus rifampin plus
streptomycin regimen were evaluated to be more effective than
other regimens in osteoarticular involvement.
There are no speciﬁc guidelines regarding the antibiotic
regimens and duration of treatment for neurobrucellosis. Most
authorities recommend the use of doxycycline in combination
with two or more other drugs, with treatment continued for
several months depending on the response. Drugs such as
doxycycline, rifampin, and co-trimoxazole have been found to
be effective due to their good CNS penetration and synergistic
actions.1 Third-generation cephalosporins diffusing into the CSF,ceftriaxone, ceftizoxime, and cefotaxime have good in vitro activity
on clinical isolates of B. melitensis.55 In our opinion, a third-
generation cephalosporin in the initial treatment of neurobrucel-
losis is essential in view of the treatment efﬁcacy, as reported by
Aygen et al.20,56 No relapse case occurred in our 34 patients treated
with triple combinations including ceftriaxone.
There is no standard therapy protocol in chronic brucellosis.
Although streptomycin, doxycycline, rifampin, and other antibiotic
combinations in conjunction with levamisole were used for
various durations, a deﬁnite treatment protocol has not been
recommended.57 In our study, levamisole was added for 6 weeks
(80 mg every other day) and the treatment duration extended to
12–24 weeks in chronic patients. This combination with extended
treatment duration appears to be successful in chronic patients.
Brucellosis is an important health problem in Turkey. The
disease has a signiﬁcant morbidity and mortality. Additionally,
since the disease primarily affects persons in their productive age,
it causes important work-power losses. Eradication of the disease
in humans can only be achieved by the control of the disease in
animals; this necessitates a multidisciplinary approach involving
both humans and animals. In addition to isolation and serological
tests, non-speciﬁc tests such as CRP and ESR should also be used in
treatment follow-up. There is no recommended treatment protocol
for complicated brucellosis. Large multicenter studies are needed
to determine the most appropriate treatment choices and
durations in complicated brucellosis.
Conﬂict of interest: No conﬂict of interest to declare.
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